Long-term and short-term outcome of multiple sclerosis: a 3-year follow-up study.

BACKGROUND The anticipated rate of short-term worsening of disability scores is the basis of power estimations in clinical trials of progressive multiple sclerosis (MS). While the clinician is most concerned in modifying the long-term outcome (eg, time to reach the Expanded Disability Status Scale [EDSS]6), the end points studied in clinical trials are those describing short-term outcome (eg, worsening of EDSS scores over 1 to 3 years). However, short-term outcome of MS may not be correlated with long-term outcome. OBJECTIVES To validate previously published models predicting time to EDSS 6. To establish predictors of short-term outcome of MS. SETTING The Ottawa, Ontario, Regional Multiple Sclerosis Clinic. PATIENTS Two hundred fifty-nine patients were followed up prospectively by a single neurologist. MAIN OUTCOME MEASURES Actuarial analysis of time to reach EDSS 6 and change in EDSS scores over a follow-up period of 1 to 3 years. RESULTS The long-term outcome in the Ottawa population was more favorable than published data from London, Ontario. Predictions of time to EDSS 6 were not strongly correlated with the degree of short-term worsening over the follow-up period. Parameters associated with a higher probability of short-term worsening were proximity of the baseline EDSS score to 4.5 and duration of MS less than 20 years. CONCLUSION Baseline EDSS and duration of MS must be considered in the design of clinical trials of progressive MS.

[1]  B. Weinshenker,et al.  The natural history of multiple sclerosis. , 1995, Neurologic clinics.

[2]  K. Syndulko,et al.  Design strategies in multiple sclerosis clinical trials , 1994 .

[3]  D. Bourdette,et al.  Inter‐ and intrarater scoring agreement using grades 1.0 to 3.5 of the Kurtzke Expanded Disability Status Scale (EDSS) , 1992, Neurology.

[4]  J. Baskerville,et al.  The natural history of multiple sclerosis: a geographically based study. 3. Multivariate analysis of predictive factors and models of outcome. , 1991, Brain : a journal of neurology.

[5]  J. Baskerville,et al.  The natural history of multiple sclerosis: a geographically based study. 4. Applications to planning and interpretation of clinical therapeutic trials. , 1991, Brain : a journal of neurology.

[6]  A V Swan,et al.  An assessment of disability rating scales used in multiple sclerosis. , 1991, Archives of neurology.

[7]  M. Clanet,et al.  Observer disagreement in rating neurologic impairment in multiple sclerosis: facts and consequences. , 1991, European neurology.

[8]  D. Wolinsky,et al.  Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: A randomized, double‐blinded, placebo‐controlled clinical trial , 1990 .

[9]  J. Noseworthy,et al.  Interrater variability with the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis clinical trial , 1990, Neurology.

[10]  B Bass,et al.  The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. , 1989, Brain : a journal of neurology.

[11]  R. Rudick,et al.  Exacerbation rates and adherence to disease type in a prospectively followed-up population with multiple sclerosis. Implications for clinical trials. , 1989, Archives of neurology.

[12]  B Bass,et al.  The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. , 1989, Brain : a journal of neurology.

[13]  L. Fratiglioni,et al.  Interrater reliability in assessing functional systems and disability on the Kurtzke scale in multiple sclerosis. , 1988, Archives of neurology.